Hearing loss specialists at Frequency pin the blame for PhIIa flop on trial design — but they couldn't stem a freefall in share price
When Frequency Therapeutics scored $80 million in cash from Astellas to jumpstart an alliance, the biotech cautiously pointed to Phase I/II data bolstering hope that they might indeed have a groundbreaking regenerative medicine approach to restoring hearing, leaning on research done by Bob Langer and Jeff Karp out of MIT around progenitor cell activation.
Newly released Phase IIa results are now keeping them away from that lofty goal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.